Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)
CNY 22.22
(0.63%)
CNY 22.22
(0.63%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 784.34 Million | 829.07 Million | 767.13 Million | 636.05 Million | 546.75 Million | 511.45 Million |
| Cost of Revenue | 135.52 Million | 129.2 Million | 126.37 Million | 105.67 Million | 85.4 Million | 72.06 Million |
| Gross Profit | 648.81 Million | 699.86 Million | 640.76 Million | 530.37 Million | 461.35 Million | 439.38 Million |
| Operating Expenses | 422.38 Million | 432.5 Million | 440.8 Million | 374.18 Million | 347.36 Million | 339.95 Million |
| Selling, General and Administrative Expenses | 360.72 Million | 356.56 Million | 355.42 Million | 309.01 Million | 292.62 Million | 289.59 Million |
| Research and Development Expenses | 49.68 Million | 47.82 Million | 50.82 Million | 48.48 Million | 39.41 Million | 33.66 Million |
| Other Expenses | 1.73 Million | 28.11 Million | 34.55 Million | 16.68 Million | 15.31 Million | -216.79 Thousand |
| Cost and Expenses | 529.62 Million | 561.71 Million | 567.18 Million | 479.85 Million | 432.77 Million | 412.02 Million |
| Operating Income | 254.72 Million | 280.87 Million | 207.15 Million | 158.9 Million | 127.77 Million | 110.3 Million |
| Interest Expense | 25.04 Million | 13.02 Million | 10.17 Million | 11.71 Million | 978.99 Thousand | 969.11 Thousand |
| Income Tax Expense | 430.87 Thousand | 452.56 Thousand | 749.28 Thousand | 1.98 Million | 1.09 Million | 2.43 Million |
| Earnings before Tax | 254.91 Million | 277.96 Million | 201.06 Million | 153.7 Million | 124.99 Million | 110.08 Million |
| Net Income | 254.48 Million | 277.78 Million | 200.82 Million | 151.71 Million | 123.89 Million | 107.65 Million |
| Earnings Per Share Basic | 1.30 | 1.44 | 1.04 | 0.82 | 0.68 | 0.59 |
| Earnings Per Share Diluted | 1.30 | 1.44 | 1.04 | 0.82 | 0.68 | 0.58 |
| Weighted Average Shares Outstanding | 195.75 Million | 192.54 Million | 193.58 Million | 184.32 Million | 183.02 Million | 181.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 195.75 Million | 192.54 Million | 193.58 Million | 184.32 Million | 183.02 Million | 184.14 Million |
| Gross Margin | 0.83 | 0.84 | 0.84 | 0.83 | 0.84 | 0.86 |
| EBIT Margin | 0.48 | 0.43 | 0.35 | 0.33 | 0.31 | 0.30 |
| Profit Margin | 0.32 | 0.34 | 0.26 | 0.24 | 0.23 | 0.21 |
| EBITDA | 379.57 Million | 372.7 Million | 278.35 Million | 220.73 Million | 175.66 Million | 158.28 Million |
| Earnings Before Tax Margin | 0.32 | 0.34 | 0.27 | 0.25 | 0.23 | 0.22 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 119.45 Million | 130.52 Million | 220.9 Million | 784.34 Million | 241.71 Million | 171.14 Million |
| Cost of Revenue | 25.99 Million | 36.63 Million | 37.74 Million | 135.52 Million | 41.07 Million | 27.76 Million |
| Gross Profit | 93.45 Million | 93.89 Million | 183.15 Million | 648.81 Million | 200.64 Million | 143.37 Million |
| Operating Expenses | 79.7 Million | 86.61 Million | 119.75 Million | 422.38 Million | 97.02 Million | 97.78 Million |
| Selling, General and Administrative Expenses | 139.21 Million | 76.95 Million | 111.93 Million | - | 62.03 Million | 112.68 Million |
| Research and Development Expenses | 8.64 Million | 9.65 Million | 11.42 Million | - | 9.83 Million | 13.28 Million |
| Other Expenses | -68.15 Million | 53.46 Thousand | 177.16 Thousand | 188.56 Thousand | -1.58 Million | -608.92 Thousand |
| Cost and Expenses | 105.69 Million | 123.25 Million | 157.49 Million | 557.91 Million | 138.09 Million | 125.55 Million |
| Operating Income | 18.17 Million | 7.27 Million | 76.69 Million | 254.72 Million | 116.82 Million | 49.65 Million |
| Interest Expense | 3.69 Million | 3.24 Million | 4.69 Million | 24.7 Million | -1.47 Million | 7.5 Million |
| Income Tax Expense | -63.04 Thousand | 219.49 Thousand | -256.55 Thousand | 430.87 Thousand | 122.14 Thousand | 190.97 Thousand |
| Earnings before Tax | 17.73 Million | 24.18 Million | 76.87 Million | 254.91 Million | 115.24 Million | 49.31 Million |
| Net Income | 17.79 Million | 23.74 Million | 77.13 Million | 254.48 Million | 115.11 Million | 49.12 Million |
| Earnings Per Share Basic | 0.09 | 0.12 | 0.39 | - | 0.59 | 0.25 |
| Earnings Per Share Diluted | 0.09 | 0.12 | 0.39 | - | 0.59 | 0.25 |
| Weighted Average Shares Outstanding | 198.24 Million | 197.16 Million | 197.76 Million | 195.75 Million | 194.16 Million | 197.16 Million |
| Weighted Average Shares Outstanding (Diluted) | 198.24 Million | 197.16 Million | 197.76 Million | 195.75 Million | 194.16 Million | 197.16 Million |
| Gross Margin | 0.78 | 0.72 | 0.83 | 0.83 | 0.83 | 0.84 |
| EBIT Margin | 0.18 | 0.25 | 0.36 | - | 0.47 | 0.34 |
| Profit Margin | 0.15 | 0.18 | 0.35 | 0.32 | 0.48 | 0.29 |
| EBITDA | 21.43 Million | 32.76 Million | 79 Million | - | 113.03 Million | 57.34 Million |
| Earnings Before Tax Margin | 0.15 | 0.06 | 0.35 | 0.32 | 0.48 | 0.29 |
3900
PNP
UPIN
CAPRO
AXLX
BAHI3